


Please type a plus sign (+) inside this box → ☐



PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/346,069
Filing Date	July 1, 1999
First Named Inventor	Keyt, Bruce
Group Art Unit	1646
Examiner Name	Kaufman, C.
Attorney Docket Number	A-62326-2/RFT/JJD

Sheet 1 of 7

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Cm	1	3,691,016		Patel	09-12-1972	
	2	3,773,919		Boswell et al.	11-20-1973	
	3	3,887,699		Yolles	06-03-1975	
	4	3,969,287		Jaworck et al.	07-13-1976	
	5	4,195,128		Hildebrand et al.	03-25-1980	
	6	4,229,537		Hodgins et al.	10-21-1980	
	7	4,247,642		Hirohara et al.	11-27-1981	
	8	4,330,440		Ayers	05-18-1982	
	9	4,399,216		Axel et al.	08-16-1983	
	10	5,073,492		Chen et al.	12-1991	
	11	5,219,739		Tischer et al.	05-15-1993	
	12	5,332,671		Ferrara et al.	07-26-1994	

RECEIVED

MAR 01 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ² (if known)				
Cm	13	CA	1 176 565		Syntex (U.S.A.) Inc.	10-23-1984		
	14	EP	0 036 776	A2	Genentech, Inc.	09-30-1981		
	15	EP	0 058 481	A1	Imperial Chemical Industries PLC	08-25-1981		
	16	EP	0 075 444	A2	Genentech, Inc.	03-30-1983		
	17	EP	0 133 988	A2	Hoechst AG	03-13-1985		
	18	EP	0 158 277	A2	Hoechst AG	10-16-1985		
	19	EP	0 160 457	A1	Genentech, Inc.	11-06-1985		
	20	EP	0 266 032	A1	Beecham Group PLC	05-04-1988		
	21	WO	87/05330	A1	Bergh, et al.	09-11-1987		
	22	WO	90/13649	A1	Genentech, Inc.	11-15-1990		
Cm	23	EP	0 506 477	A	Ferrara et al.	09-1990		


Examiner Signature	<i>Clair M. Kaufman</i>	Date Considered	4/30/01
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	09/346,069	
				Filing Date	July 1, 1999	
				First Named Inventor	Keyt, Bruce	
				Group Art Unit	1646	
				Examiner Name	Kaufman, C.	
Attorney Docket Number	A-62326-2/RFT/JJD					
Sheet	2	of	7			

RECEIVED

MAR 01 2001

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ch	24	ADELMAN et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," <i>DNA</i> 2(3):183-193 (1983)	
	25	AIELLO et al., "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders," <i>New England J of Medicine</i> 331(22):1480-1487 (1994)	
	26	ALPIN et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids," <i>CRC Crit. Rev. Biochem.</i> 10(4):259-306 (1981)	
	27	AVIV et al., "Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic Acid-Cellulose," <i>Proc. Natl. Acad. Sci. USA</i> 69(6):1408-1412 (1972)	
	28	BAENZIGER, "The Oligosaccharides of Plasma Glycoproteins: Synthesis, Structure, and Function," in <i>The Plasma Proteins: Structure, Function, and Genetic Control</i> , F.W. Putnam, eds. 2d edition, Academic Press: New York, Vol. IV, Chapter 5, pp. 271-315 (1984)	
	29	BARZU et al., "Binding and endocytosis of heparin by human endothelial cells in culture," <i>Biochimica et Biophysica Acta</i> 845:196-203 (1985)	
	30	BENTON et al., "Screening λ gt recombinant clones by hybridization to single plaques in situ," <i>Science</i> 196:180-182 (1977)	
	31	BOLIVAR et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System," <i>Gene</i> 2:95-113 (1977)	
	32	BOTHWELL et al., "Dual expression of λ genes in the MOPC-315 plasmacytoma," <i>Nature</i> 290:65-67 (1981)	
	33	BREIR et al., "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Dev.</i> 114:521-532 (1992)	
	34	CHANG, "Are World Summits Really Necessary," <i>Nature</i> 375:615 (1978)	
	35	CHEN et al., "High-efficiency transformation of mammalian cells by plasmid DNA," <i>Mol. Cell. Biol.</i> 7(8):2745-2752 (1987)	
	36	COHEN, et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia Coli by R-Factor DNA," <i>Proc. Natl. Acad. Sci. USA</i> 69(8):2110-2114 (1972)	
	37	CREA et al., "Chemical Synthesis of Genes for Human Insulin," <i>Proc. Natl. Acad. Sci. USA</i> 75(12):5765-5769 (1978)	
Ch	38	CREIGHTON, T.E., <i>Proteins: Structure and Molecular Principles</i> , W.H. Freeman & Co.: San Francisco pp. 79-86 (1983)	

Examiner Signature	<i>Chen M. 10/2</i>	Date Considered	4/30/01
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/346,069
		Filing Date	July 1, 1999
		First Named Inventor	Keyt, Bruce
		Group Art Unit	1646
		Examiner Name	Kaufman, C.
Attorney Docket Number	A-62326-2/RFT/JJD		
Sheet	3	of	7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
clw	39	FERRARA et al., "Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells," <i>Biochem. & Biophys. Res. Comm.</i> 161(2):851-858 (1989)	
	40	FERRARA, N., "Vascular endothelial growth factor. The trigger for neovascularization in the eye," <i>Laboratory Investigation</i> 72(6):615-618 (1995)	
	41	FIERS et al., "Complete Nucleotide Sequences of SV40 DNA," <i>Nature</i> 273:113-120 (1990)	
	42	FROEHLER, et al., "Synthesis of DNA via Deoxynucleoside H-phosphonate Intermediates," <i>Nucleic Acids Research</i> 14(13):5399-5407 (1986)	
	43	GEORGE et al., "Mutation data matrix and its uses," <i>Meth. Enzymol.</i> 183:333-351 (1990)	
	44	GOEDDEL et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone," <i>Nature</i> 281:544-548 (1979)	
	45	GOEDDEL et al., "Synthesis of Human Fibroblast Interferon by E. coli," <i>Nucleic Acids Research</i> 8(18):4057-4074 (1980)	
	46	GORMAN et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line," <i>DNA Prot. Eng. Tech.</i> 2(1):3-10 (1990)	
	47	GRAHAM et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," <i>Virology</i> 52:456-467 (1973)	
	48	GREEN, et al., "Human β -globin pre-mRNA synthesized in vitro is accurately spliced in Xenopus oocyte nuclei," <i>Cell</i> 32(3):681-694 (1983)	
	49	HANIU et al., "Disulfide bonds in recombinant human platelet-derived growth factor BB dimer: characterization of intermolecular and intramolecular disulfide linkages," <i>Biochemistry</i> 32:2431-2437 (1993)	
	50	HESS et al., "Cooperation of Glycolytic Enzymes," <i>Advances in Enzyme Regulation</i> George Weber, New York: Pergamon Press, Vol. 7, pp. 149-167 (1968)	
	51	HITZEMAN et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique," <i>Journal of Biological Chemistry</i> 255(24):12073-12080 (1980)	
	52	HOLLAND et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase," <i>Biochemistry</i> 17(23):4900-4907 (1978)	
u	53	HOUCK et al., "Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms," <i>Journal of Biological Chemistry</i> 267:26031-26037 (1992)	


Examiner Signature	<i>Clw M. Kaufman</i>	Date Considered	9/30/01
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FILE COPY



Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/346,069
		Filing Date	July 1, 1999
		First Named Inventor	Keyt, Bruce
		Group Art Unit	1646
		Examiner Name	Kaufman, C.
Attorney Docket Number	A-62326-2/RFT/JJD		
Sheet	4	of	7

RECEIVED

MAR 01 2001

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
C	54	HSIAO, et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg ⁴ Gene," <i>Proc. Natl. Acad. Sci. USA</i> 76:3829-3833 (1979)	
	55	HUNTER et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity," <i>Nature</i> 194:495-496 (1962)	
	56	HUYNH, et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," <i>DNA Cloning: A Practical Approach</i> , D.M. Glover, Vol. 1, pp. 49-78 (1985)	
	57	ITAKURA et al., "Expression in Escherichia Coli of a Chemically Synthesized Gene for the Hormone Somatostatin," <i>Science</i> 198:1056-1063 (1977)	
	58	JONES, E., "Proteinase Mutants of Saccharomyces Cerevisiae," <i>Genetics</i> 85(1):23-33 (1977)	
	59	KENDALL et al., "Specificity of Vascular Endothelial Cell Growth Factor Receptor Ligand Binding Domains," <i>Biochem. Biophys. Res.</i> 201(1):326-330 (1994)	
	60	KEYT et al., "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency," <i>Journal of Biological Chemistry</i> 271(13):7788-7795 (1996)	
	61	KEYT et al., "Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors," <i>Journal of Biological Chemistry</i> 271(10):5638-5646 (1996)	
	62	KIM et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies," <i>Growth Factors</i> 7(1):53-64 (1992)	
	63	KINGSMAN et al., "Replication in Saccharomyces Cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region," <i>Gene</i> 7:141-152 (1979)	
	64	KUKURUZINSKA et al., "Protein glycosylation in yeast," <i>Annu. Rev. Biochem.</i> 56:915-944 (1987)	
	65	KUNKEL et al., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection," <i>Methods in Enzymology</i> 154:367-382 (1987)	
	66	KUNKEL, T., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection," <i>Proc. Natl. Acad. Sci. USA</i> 82:488-492 (1985)	
	67	LANGER, "Controlled Release of Macromolecules," <i>Chem. Tech.</i> 12:98-105 (1982)	
	68	LAWN et al., "The Sequence of Human Serum Albumin cDNA and its Expression in E. Coli," <i>Nucleic Acids Research</i> 9(22):6103-6114 (1981)	

Examiner Signature	<i>Charles M. Kaufman</i>	Date Considered	4/30/01
--------------------	---------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/346,069
				Filing Date	July 1, 1999
				First Named Inventor	Keyt, Bruce
				Group Art Unit	1646
				Examiner Name	Kaufman, C.
				Attorney Docket Number	A-62326-2/RFT/JJD
Sheet	5	of	7		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cu	69	LUSKY and BOTCHEN, "Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences," <i>Nature</i> 293:79-81 (1981)	
	70	MAHER et al., "Alanine Mutagenesis of Conserved Residues in the Platelet-Derived Growth Factor Family: Identification of Residues Necessary for Dimerization and Transforamtion," <i>Oncogenes</i> 8:533-541 (1993)	
	71	MANDEL et al., "Calcium-dependent Bacteriophage DNA Infection" <i>J. Mol. Biol.</i> 53:159-162 (1970)	
	72	MANIATIS et al., <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, pp. 31, 90-91, 133-134 (1982)	
	73	MANIATIS et al., "The Isolation of Structural Genes from Libraries of Eucaryotic DNA," <i>Cell</i> 15:687-701 (1978)	
	74	MARSHALL, R.D., "The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins," <i>Biochem. Soc. Symp.</i> 40:17-26 (1974)	
	75	MAXAM et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages," <i>Methods in Enzymology</i> 65:499-560 (1980)	
	76	MESSING et al., <i>Proceedings of the Third Cleveland Symposim on Macromolecules: Recombinant DNA</i> , Walton, A., Elsevier: Amsterdam, pp. 143-153 (1981)	
	77	MESSING et al., "A System for Shotgun DNA Sequencing," <i>Nucleic Acids Research</i> 9(2):209-321 (1981)	
	78	NAKAMAYE, et al., "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," <i>Nucleic Acids Research</i> 14(24):9679-9698 (1986)	
	79	NORRIS, et al., "Asymmetric linker molecules for recombinant DNA constructions," <i>Gene</i> 7(3-4):355-362 (1979)	
	80	OEFFNER et at., "Crystal structure of human platelet-derived growth factor BB" <i>EMBO J.</i> 11(11):3921-3926 (1992)	
	81	PARK et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR," <i>Journal of Biological Chemistry</i> 269(41):25646-25654 (1994)	
	82	POTGENS et al., "Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutation," <i>Journal of Biological Chemistry</i> 269(52):32879-32885 (1994)	
cu	83	SAMBROOK et al., <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, Part 1:C 5.28-5.32 (1989).	

Examiner Signature	<i>Clare M. K.</i>	Date Considered	4/30/01
--------------------	--------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/346,069
		Filing Date	July 1, 1999
		First Named Inventor	Keyt, Bruce
		Group Art Unit	1646
		Examiner Name	Kaufman, C.
Attorney Docket Number	A-62326-2/RFT/JJD		
Sheet	6	of	7


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Cur	84	SANGER et al., "DNA Sequencing with Chain-terminating Inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 74(12):5463-5467 (1977)	
	85	SCHULZ et al., <i>Principles of Protein Structure</i> , Springer Verlag: New York, NY, pp. 14-16 (1979)	
	86	SIDMAN et al., "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid," <i>Biopolymers</i> 22(1):547-556 (1983)	
	87	SIEBENLIST et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters," <i>Cell</i> 20:269-281 (1980)	
	88	SOUTHERN, E., "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis," <i>J. Mol. Biol.</i> 98:503-517 (1975)	
	89	STINCHCOMB, et al., "Isolation and Characterization of a Yeast Chromosomal Replicator," <i>Nature</i> 282:39-43 (1979)	
	90	STRUCK and LENNARZ, "The Function of Saccharide-Lipids in Synthesis of Glycoproteins," <i>The Biochemistry of Glycoproteins and Proteoglycans</i> , W. J. Lennarz, Plenum Press, Chapter 2, pp. 35-83 (1980)	
	91	TANNER and LEHLE, "Protein glycosylation in yeast," <i>Biochimica et Biophysica Acta</i> 906(1):81-99 (1987)	
	92	TAYLOR et al., "Efficient Transcription of RNA into DNA by Avian Sarcoma Virus Polymerase," <i>Biochimica et Biophysica Acta</i> , 442:324-330 (1976)	
	93	TSCHUMPER et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene," <i>Gene</i> 10:157-166 (1980)	
	94	ULLRICH et al., "Rat insulin genes: construction of plasmids containing the coding sequences," <i>Science</i> 196:1313-1319 (1977)	
	95	URLAUB, et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity," <i>Proc. Natl. Acad. Sci. USA</i> 77(7):4216-4220 (1980)	
	96	VAN SOLINGEN et al., "Fusion of Yeast Spheroplasts," <i>J. Bact.</i> 130:946-947 (1977)	
	97	VIEIRA and MESSING, "The pUC plasmids, and M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers," <i>Gene</i> 19(3):259-268 (1982)	
	98	VIEIRA et al., "Production of Single-stranded Plasmid DNA," <i>Methods in Enzymology</i> 153:3-11 (1987)	
Cur	99	WARTELL and REZNIKOFF, "Cloning DNA restriction endonuclease fragments with protruding single-stranded ends," <i>Gene</i> 9(3-4):307-319 (1980)	

Examiner Signature	<i>Clara M. Kef</i>	Date Considered	4/30/01
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


 O I P E J C I 137
 FEB 28 2001
 PATENT & TRADEMARK OFFICE

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/346,069
				Filing Date	July 1, 1999
				First Named Inventor	Keyt, Bruce
				Group Art Unit	1646
				Examiner Name	Kaufman, C.
				Attorney Docket Number	A-62326-2/RFT/JJD
Sheet	7	of	7		

[illegible]

Examiner Signature	<i>Clare M. Lutz</i>	Date Considered	4/30/01
-----------------------	----------------------	--------------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.